{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T23:46:27Z","timestamp":1784331987873,"version":"3.55.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2017,4,19]],"date-time":"2017-04-19T00:00:00Z","timestamp":1492560000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1245\/s10434-017-5827-1","type":"journal-article","created":{"date-parts":[[2017,4,19]],"date-time":"2017-04-19T17:27:04Z","timestamp":1492622824000},"page":"2282-2290","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["Preoperative Chemoradiotherapy Versus Perioperative Chemotherapy for Patients With Resectable Esophageal or Gastroesophageal Junction Adenocarcinoma"],"prefix":"10.1245","volume":"24","author":[{"given":"M. C. J.","family":"Anderegg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. C.","family":"van der Sluis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. P.","family":"Ruurda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. S.","family":"Gisbertz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. C. C. M.","family":"Hulshof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"van Vulpen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N. Haj","family":"Mohammed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. W. M.","family":"van Laarhoven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. J.","family":"Wiezer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Los","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. I.","family":"van Berge Henegouwen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"van Hillegersberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,4,19]]},"reference":[{"key":"5827_CR1","doi-asserted-by":"crossref","unstructured":"Pennathur A, Gibson MK, Jobe BA, et al. Oesophageal carcinoma. Lancet. 2013;381:400\u201312. Retrieved 29 January 2014 at http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/23374478 .","DOI":"10.1016\/S0140-6736(12)60643-6"},{"key":"5827_CR2","doi-asserted-by":"crossref","unstructured":"Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin. 2011;61:69\u201390. Retrieved 21 March 2014 at http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/21296855 .","DOI":"10.3322\/caac.20107"},{"key":"5827_CR3","unstructured":"Kelsen DP, Ginsberg R, Pajak TF, et al. Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med. 1998;339:1979\u201384. Retrieved 22 September 2015 at http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/9869669 ."},{"key":"5827_CR4","doi-asserted-by":"crossref","unstructured":"Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355:11\u201320. Retrieved 13 May 2014 at http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/16822992 .","DOI":"10.1056\/NEJMoa055531"},{"key":"5827_CR5","doi-asserted-by":"crossref","unstructured":"Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial. Lancet London Engl. 2002;359:1727\u201333. Retrieved 22 September 2015 at http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/12049861","DOI":"10.1016\/S0140-6736(02)08651-8"},{"key":"5827_CR6","doi-asserted-by":"crossref","unstructured":"Tepper J, Krasna MJ, Niedzwiecki D, et al. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol. 2008;26:1086\u201392. Retrieved 22 September 2015 at http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/18309943 .","DOI":"10.1200\/JCO.2007.12.9593"},{"key":"5827_CR7","doi-asserted-by":"crossref","unstructured":"Walsh TN, Noonan N, Hollywood D, et al. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med. 1996;335:462\u20137. Retrieved 22 September 2015 at http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/8672151 .","DOI":"10.1056\/NEJM199608153350702"},{"key":"5827_CR8","doi-asserted-by":"crossref","unstructured":"van Hagen P, Hulshof MCCM, van Lanschot JJB, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012;366:2074\u201384. Retrieved 20 April 2014 at http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/22646630 .","DOI":"10.1056\/NEJMoa1112088"},{"key":"5827_CR9","doi-asserted-by":"crossref","unstructured":"Sjoquist KM, Burmeister BH, Smithers BM, et al. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol. 2011;12:681\u201392. Retrieved 5 May 2015 at http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/21684205 .","DOI":"10.1016\/S1470-2045(11)70142-5"},{"key":"5827_CR10","doi-asserted-by":"crossref","unstructured":"Stahl M, Walz MK, Stuschke M, et al. Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol. 2009;27:851\u20136. Retrieved 6 January 2016 at http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/19139439 .","DOI":"10.1200\/JCO.2008.17.0506"},{"key":"5827_CR11","doi-asserted-by":"crossref","unstructured":"Burmeister BH, Thomas JM, Burmeister EA, et al. Is concurrent radiation therapy required in patients receiving preoperative chemotherapy for adenocarcinoma of the oesophagus? A randomised phase II trial. Eur J Cancer. 2011;47:354\u201360. Retrieved 8 December 2015 at http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/21084184 .","DOI":"10.1016\/j.ejca.2010.09.009"},{"key":"5827_CR12","doi-asserted-by":"crossref","unstructured":"Klevebro F, Johnsen G, Johnson E, et al. Morbidity and mortality after surgery for cancer of the oesophagus and gastro-oesophageal junction: a randomized clinical trial of neoadjuvant chemotherapy vs neoadjuvant chemoradiation. Eur J Surg Oncol. 2015;41:920\u20136. Retrieved 12 April 2016 at http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/25908010 .","DOI":"10.1016\/j.ejso.2015.03.226"},{"key":"5827_CR13","doi-asserted-by":"crossref","unstructured":"Sumpter K, Harper-Wynne C, Cunningham D, et al. Report of two protocol planned interim analyses in a randomised multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric cancer receiving ECF. Br J Cancer. 2005;92:1976\u201383. Retrieved 22 September 2015 at http:\/\/www.pubmedcentral.nih.gov\/articlerender.fcgi?artid=2361798&tool=pmcentrez&rendertype=abstract .","DOI":"10.1038\/sj.bjc.6602572"},{"key":"5827_CR14","doi-asserted-by":"crossref","unstructured":"van der Sluis PC, Ubink I, van der Horst S, et al. Safety, efficacy, and long-term follow-up evaluation of perioperative epirubicin, cisplatin, and capecitabine chemotherapy in esophageal resection for adenocarcinoma. Ann Surg Oncol. 2015;22:1555\u201363. Retrieved 12 April 2016 at http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/25564156 .","DOI":"10.1245\/s10434-014-4120-9"},{"key":"5827_CR15","doi-asserted-by":"crossref","unstructured":"Haverkamp L, van der Sluis PC, Verhage RJ, et al. End-to-end cervical esophagogastric anastomoses are associated with a higher number of strictures compared with end-to-side anastomoses. J Gastrointest Surg. 2013;17:872\u20136. Retrieved 12 April 2016 at https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/23400509 .","DOI":"10.1007\/s11605-013-2159-8"},{"key":"5827_CR16","doi-asserted-by":"crossref","unstructured":"Dindo D, Demartines N, Clavien P. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240:205\u201313. Retrieved 12 April 2016 at https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/15273542 .","DOI":"10.1097\/01.sla.0000133083.54934.ae"},{"key":"5827_CR17","unstructured":"Sobin LH, Gospodarowicz MK, Wittekind C. TNM Classification of Malignant Tumors. 7th ed. Wiley-Blackwell, Oxford 2009. Retrieved 12 April 2016"},{"key":"5827_CR18","doi-asserted-by":"crossref","unstructured":"Dikken JL, Lemmens VE, Wouters MW, et al. Increased incidence and survival for oesophageal cancer but not for gastric cardia cancer in the Netherlands. Eur J Cancer. 2012;48:1624\u201332. Retrieved 12 April 2016 at https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/22317953 .","DOI":"10.1016\/j.ejca.2012.01.009"},{"key":"5827_CR19","doi-asserted-by":"crossref","unstructured":"Kumagai K, Rouvelas I, Tsai JA, et al. Meta-analysis of postoperative morbidity and perioperative mortality in patients receiving neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal and gastro-oesophageal junctional cancers. Br J Surg. 2014;101:321\u201338. Retrieved 12 April 2016 at http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/24493117 .","DOI":"10.1002\/bjs.9418"},{"key":"5827_CR20","unstructured":"Shapiro J, van Lanschot JJB, Hulshof MCCM, et al. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. Lancet Oncol. 2015;16:1090\u20138. Retrieved 12 April 2016 at http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/26254683 ."},{"key":"5827_CR21","doi-asserted-by":"crossref","unstructured":"Prithviraj GK, Baksh K, Fulp W, et al. Carboplatin and paclitaxel as first-line treatment of unresectable or metastatic esophageal or gastric cancer. Dis Esophagus. 2015;28:782\u20137. Retrieved 12 April 2016 at http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/25155802 .","DOI":"10.1111\/dote.12279"},{"key":"5827_CR22","unstructured":"ICORG 10-14. Neo-AEGIS: A randomized clinical trial of neoadjuvant and adjuvant chemotherapy (modified MAGIC regimen) versus neoadjuvant chemoradiation (CROSS protocol) in adenocarcinoma of the esophagus and esophagogastric junction. 2014 ASCO Annual Me. Retrieved 24 January 2016 at http:\/\/meetinglibrary.asco.org\/content\/130909-144 ."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1245\/s10434-017-5827-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-017-5827-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-017-5827-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,21]],"date-time":"2019-09-21T09:12:17Z","timestamp":1569057137000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1245\/s10434-017-5827-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4,19]]},"references-count":22,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2017,8]]}},"alternative-id":["5827"],"URL":"https:\/\/doi.org\/10.1245\/s10434-017-5827-1","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,4,19]]}}}